

HPV: More than 80 Percent of Sexually Active Women Get Infected; the CBCD Reviews a Report

"One huge problem with assessing the extent of HPV in the population is that not all people develop symptoms or signs of infection." (1)

ROCHESTER, NY, UNITED STATES,
December 3, 2015 /EINPresswire.com/ --

"Infected with the human papillomavirus (HPV)? We recommend taking [Gene-Eden-VIR](#) or [Novirin](#)." – Greg Bennett, CBCD

More than 80% of all sexually active women in the United States will become infected with a strain of the human papillomavirus (HPV), according to a report by the Centers for Disease Control and Prevention (CDC). (1) Even more men are expected to become infected, with infection rates reaching 90%. A report in the Orlando Sentinel notes that "HPV is dangerous because long-standing infection can lead to several conditions. Two of the most common are venereal warts and cervical cancer. Less common are cancers of the mouth and anal areas. Venereal warts range from almost undetectable to huge, cauliflower-like growths that can appear on the genital areas, in the vagina and in the mouth. Cervical cancer is one of the most common cancers in women, and nearly all cases of cervical cancers are thought to be the result of undetected HPV infection. HPV also causes 90 percent of all anal cancers, 70 percent of cancers of the mouth and throat, 65 percent of cancers of the vagina and 35 percent of cancers of the penis." (1)



The Center for the Biology of Chronic Disease (CBCD) recommends that anyone who may be

HPV.

Click to learn more about [HPV symptoms](#).

The formula of these natural antiviral products was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Novirin and Gene-Eden-VIR formula is effective against the HPV and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the HPV...reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (2) The study authors also wrote that “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (2)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites here:

<http://www.novirin.com>

and

<http://www.gene-eden-vir.com>

Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

Note: Novirin has the same formula as Gene-Eden-VIR. However, it contains higher quality and more expensive ingredients.

It is important for the public to understand that “An HPV infection can take as long as 10-30 years to cause cancer. Detection is a challenge because the only tests approved by the Food and Drug Administration involve sampling cervical cells and checking them for the presence of DNA from the virus. There is neither a screening test for HPV in other parts of the body nor a test for men.” (1)

What Treatments are Available for HPV infections?

“There are no drugs approved against the HPV. Current treatments include procedures, such as cryotherapy, conization, and the Loop Electrosurgical Excision Procedure (LEEP). These procedures use liquid nitrogen, a surgical knife (scalpel), a carbon dioxide (CO2) laser, or electrical current to remove the abnormal growths caused by the HPV. These growths include cells that harbor the active virus. The procedures do not target cells with the latent virus. Since they do not remove the latent virus, these procedures only produce a temporary remission.” (2) In contrast, Novirin and Gene-Eden-VIR were designed to target the latent HPV, and were shown to reduce HPV symptoms in two separate post-marketing clinical studies that followed FDA guidelines.

The CBCD therefore recommends that individuals infected with the latent HPV take Novirin or Gene-Eden-VIR.

The CBCD reminds the public that Gene-Eden-VIR and Novirin are not a cure. However, two clinical studies, published in peer reviewed medical journals showed that their formula decreases symptoms in infected individuals. Specifically, the formula of Gene-Eden-VIR and Novirin was shown to safely and effectively reduce HPV symptoms. Additionally, it was designed to help the immune system target the latent virus.

Find us on Facebook here: <https://www.facebook.com/GeneEdenVIR>

Follow us Twitter here: @HananPolansky

All orders of Gene-Eden-VIR and Novirin are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) Bosshardt, R. "HPV virus will strike more than 80 percent of sexually active adults" Orlando Sentinel, Published December 6, 2015

<http://www.orlandosentinel.com/news/lake/os-lk-housecalls-12062015-20151206-story.html>

(2) Polansky H, Itzkovitz E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Pharmacology & Pharmacy, 2013, 4, 1-8 <http://dx.doi.org/10.4236/pp.2013.46A001>

Greg Bennett
CBCD
585-250-9999
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.

